Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | WNT3A | P56704 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31268787 | 0.94 | KCNH2 (0.33) | PIK3CDKCNH2CNR1SCN5ASCN9A | |
| SCHEMBL31269090 | 0.90 | HTR6 (0.35) | PIK3CDKCNH2CNR1SCN5ASCN9A | |
| SCHEMBL30983587 | 0.90 | HTR6 (0.36) | PIK3CDCNR1IGF1RMETTL3 | |
| SCHEMBL31269289 | 0.89 | PIK3CD (0.34) | PIK3CDKCNH2CNR1SCN5ASCN9A | |
| SCHEMBL31269320 | 0.88 | HTR6 (0.34) | PIK3CDKCNH2CNR1SCN5ASCN9A | |
| SCHEMBL31269287 | 0.88 | DPP4 (0.36) | NTRK1PIK3CDDPP4 | |
| SCHEMBL31269124 | 0.87 | CNR1 (0.33) | PIK3CDKCNH2CNR1SCN5ASCN9A | |
| SCHEMBL31268829 | 0.86 | THRB (0.39) | NTRK1LCKKDRPIK3CDKCNH2 | |
| SCHEMBL31268791 | 0.86 | CNR1 (0.39) | PIK3CDKCNH2CNR1SCN5ASCN9A | |
| SCHEMBL31269236 | 0.85 | PIK3CD (0.34) | PIK3CDKCNH2CNR1SCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |